[Skip to Content]
[Skip to Content Landing]
January 1972

Drugs and Their Use

Author Affiliations

Grosse Pointe, Mich

Arch Dermatol. 1972;105(1):127. doi:10.1001/archderm.1972.01620040087025

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


To the Editor.—  This letter is written in the hope of stimulating an exchange of ideas on a controversial subject pertinent to our present practice.The American dermatologist is presented with a moral and ethical dilemma in deciding whether or not to use methotrexate in extensive or complicated psoriasis. We are all trained to do what we must in order to make life livable for our patients. At times, calculated risks must be taken but we accept these, as does the informed patient after due consideration.In the severe or complicated psoriatic (I am not considering the problem of the inconvenienced moderate or mild psoriatic) antimetabolites present a recognized method of treatment which will produce relief in a reasonable number of patients with only moderate risk if properly administered.Yet we have no recognition by the Federal Drug Administration that a drug such as methotrexate exists as acceptable treatment for

First Page Preview View Large
First page PDF preview
First page PDF preview